Developer docs
API playgroundTry for free, no card

Search company profiles

Steba Biotech

Full company profile

uuid0009b83

Namestring
Steba Biotech
Legal namestring
ImPact Biotech
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Steba Biotech, operating under the name ImPact Biotech, is a privately held, clinical-stage biotechnology company founded in 1996 and headquartered in New York, United States. The firm is built around a single proprietary platform — Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) — a light-activated oncology technology designed to deliver surgery-like efficacy for the treatment of solid tumors in patients who are ineligible for surgical intervention or for whom surgery would be debilitating. The platform's core mechanism uses a photosensitizer activated by targeted illumination to disrupt tumor vasculature, enabling precise, organ-sparing treatment across multiple solid tumor indications.

The company is applying Padeliporfin VTP across a development pipeline covering four oncology indications: Upper Tract Urothelial Carcinoma (UTUC), Lung Cancer, Esophageal Cancer, and Pancreatic Cancer. All four programs are pipeline-stage with no commercialized product. The organization's stated go-to-market posture is to actively seek strategic and co-development partnerships to advance the platform, rather than build a standalone commercial sales force; investor relations and partnership outreach appear to be the primary commercial channels currently active.

Steba Biotech operates with 1-10 employees and discloses no commercial revenue, pricing, or customer base. The leadership team identified in available sources includes Barak Palatchi as CEO and Raphael Harari as Founder. The business model is therefore pre-commercial: value is generated through clinical advancement of the VTP platform, capture of development-stage milestones, and eventual partnership or licensing revenue tied to regulatory progress. Distribution channels, pricing models, and named institutional investors are not disclosed in the input data.

Short descriptiontext

Steba Biotech (operating as ImPact Biotech) is a clinical-stage biotechnology company developing Padeliporfin VTP, a vascular-targeted photodynamic therapy platform that treats solid tumors in patients ineligible for or unsuitable for surgery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
vascular targeted photodynamic therapy, solid tumor oncology, photo-activated cancer therapy, biopharmaceutical drug development, oncology therapeutics pipeline
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Steba Biotech (operating as ImPact Biotech) is a private biopharmaceutical company developing Padeliporfin VTP (Vascular Targeted Photodynamic therapy), a targeted oncology platform for the treatment of solid tumors. The platform uses the drug Padeliporfin activated by targeted laser light to selectively destroy tumor vasculature, with a development pipeline targeting UTUC, lung, esophageal, and pancreatic cancers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ImPact Biotech (Steba Biotech) operates a single-platform approach built around its core Padeliporfin VTP (Vascular Targeted Photodynamic) technology. This novel oncology platform is designed to treat solid tumors by using light-activated therapy that targets tumor vasculature. The platform is being applied across multiple cancer indications in the development pipeline, including Upper Tract Urothelial Carcinoma (UTUC), Lung Cancer, Esophageal Cancer, and Pancreatic Cancer. The VTP technology offers surgery-like efficacy as an alternative for patients who are ineligible for surgery or for whom surgery would be debilitating.

Product and service5 records
1Padeliporfin VTP (Vascular Targeted Photodynamic Therapy)
CategoryOncology Therapeutics
Description

Padeliporfin VTP is a proprietary photo-activated oncology platform that uses the drug Padeliporfin combined with targeted laser light to selectively destroy tumor vasculature. It is being developed as a treatment for solid tumors and is intended for oncology specialists and hospital oncology/urology departments.

2Padeliporfin VTP for Upper Tract Urothelial Carcinoma (UTUC)
CategoryOncology Therapeutics
Description

An application of Steba Biotech's Padeliporfin VTP platform targeting Upper Tract Urothelial Carcinoma (UTUC), a rare urological cancer of the upper urinary tract. In development stage, intended for urology and oncology specialists treating UTUC patients.

3Padeliporfin VTP for Lung Cancer
CategoryOncology Therapeutics
Description

An application of Steba Biotech's Padeliporfin VTP platform targeting lung cancer. In development stage, intended for thoracic oncologists and pulmonology/oncology departments.

4Padeliporfin VTP for Esophageal Cancer
CategoryOncology Therapeutics
Description

An application of Steba Biotech's Padeliporfin VTP platform targeting esophageal cancer. In development stage, intended for gastroenterology oncologists and oncology departments.

5Padeliporfin VTP for Pancreatic Cancer
CategoryOncology Therapeutics
Description

An application of Steba Biotech's Padeliporfin VTP platform targeting pancreatic cancer. In development stage, intended for gastrointestinal oncologists and oncology surgical departments.

Partnership1 partner
1Open to Partnering
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ImPact Biotech is actively seeking partnerships with organizations that share their vision for transforming the treatment paradigm in oncology. The company emphasizes that transforming treatment paradigms requires both innovation and strong collaborations. They welcome inquiries from organizations interested in working with ImPact Biotech to advance their VTP technology platform.

impactbiotech.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Rakuten Medical develops photoimmunotherapy (Alluminox platform), a light-activated oncology therapy that selectively targets tumor cells. It is the most directly comparable peer to ImPact Biotech, as both pursue light-activated, vascular- or cell-targeted oncology platforms in solid tumors.

TypeDirect peer
Description

Theralase is a clinical-stage photodynamic therapy company developing light-activated drug conjugates for non-muscle invasive bladder cancer and other solid tumors. It competes with ImPact Biotech in the PDT-oncology space, particularly for urological indications like UTUC.

TypeDirect peer
Description

PhotoCure commercializes Hexvix/Cysview, a photodynamic diagnostic and therapy platform used in bladder cancer management. It is a directly relevant peer in the PDT space and shares the urology-oncology overlap relevant to ImPact Biotech's UTUC program.

TypeEmerging player
Description

Soligenix is developing SGX301 (synthetic hypericin) photodynamic therapy for cutaneous T-cell lymphoma and has oncology and PDT expertise. It is an emerging peer with narrower indications but a directly comparable light-activated oncology mechanism.

5Biolitec Pharma
TypeDirect peer
Description

Biolitec develops and commercializes laser-based photodynamic therapy systems and photosensitizing drugs for multiple solid tumor and benign indications. It is a direct commercial peer in the broader oncology PDT market.

TypeOthers
Description

Modulight manufactures medical laser systems used as the light-delivery component in photodynamic therapy, including oncology applications. It is a key enabling technology supplier to PDT developers like ImPact Biotech rather than a direct competitor.

TypeBroad incumbent
Description

AstraZeneca is a broad incumbent in oncology with approved therapies across lung, esophageal, and other solid tumors that overlap with ImPact Biotech's pipeline indications. It is relevant as a competitive force and a potential strategic acquirer or partner.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb is a major oncology incumbent with leading immunotherapy franchises (Opdivo, Yervoy) targeting lung and other solid tumors overlapping with ImPact Biotech's pipeline. It represents the competitive standard of care in multiple ImPact indications.

TypeBroad incumbent
Description

Jazz Pharmaceuticals markets Zepzelca (lurbinectedin) for small cell lung cancer and has a broader oncology specialty franchise, including in urological cancers. It is a relevant commercial peer in ImPact Biotech's lung and UTUC indications.

TypeDirect peer
Description

UroGen Pharma develops specialty therapeutics for urothelial cancers, including Jelmyto for upper tract urothelial carcinoma (UTUC) — the same lead indication targeted by ImPact Biotech. It is a directly relevant peer for the UTUC opportunity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Steba Biotech

Oncology Therapeuticsstebabiotech.com

Steba Biotech (operating as ImPact Biotech) is a clinical-stage biotechnology company developing Padeliporfin VTP, a vascular-targeted photodynamic therapy platform that treats solid tumors in patients ineligible for or unsuitable for surgery.

What Steba Biotech does

Steba Biotech, operating under the name ImPact Biotech, is a privately held, clinical-stage biotechnology company founded in 1996 and headquartered in New York, United States. The firm is built around a single proprietary platform — Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) — a light-activated oncology technology designed to deliver surgery-like efficacy for the treatment of solid tumors in patients who are ineligible for surgical intervention or for whom surgery would be debilitating. The platform's core mechanism uses a photosensitizer activated by targeted illumination to disrupt tumor vasculature, enabling precise, organ-sparing treatment across multiple solid tumor indications.

The company is applying Padeliporfin VTP across a development pipeline covering four oncology indications: Upper Tract Urothelial Carcinoma (UTUC), Lung Cancer, Esophageal Cancer, and Pancreatic Cancer. All four programs are pipeline-stage with no commercialized product. The organization's stated go-to-market posture is to actively seek strategic and co-development partnerships to advance the platform, rather than build a standalone commercial sales force; investor relations and partnership outreach appear to be the primary commercial channels currently active.

Steba Biotech operates with 1-10 employees and discloses no commercial revenue, pricing, or customer base. The leadership team identified in available sources includes Barak Palatchi as CEO and Raphael Harari as Founder. The business model is therefore pre-commercial: value is generated through clinical advancement of the VTP platform, capture of development-stage milestones, and eventual partnership or licensing revenue tied to regulatory progress. Distribution channels, pricing models, and named institutional investors are not disclosed in the input data.

Steba Biotech firmographics

Firmographics
Name
Steba Biotech
Legal name
ImPact Biotech
Website
https://stebabiotech.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
Steba Biotech (operating as ImPact Biotech) is a clinical-stage biotechnology company developing Padeliporfin VTP, a vascular-targeted photodynamic therapy platform that treats solid tumors in patients ineligible for or unsuitable for surgery.
Ownership category
akta.pro rank

Steba Biotech industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Vascular targeted photodynamic therapy
  • Solid tumor oncology
  • Photo-activated cancer therapy
  • Biopharmaceutical drug development
  • Oncology therapeutics pipeline

Where Steba Biotech is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Steba Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Steba Biotech product offering

Product offering

Core offering

Steba Biotech (operating as ImPact Biotech) is a private biopharmaceutical company developing Padeliporfin VTP (Vascular Targeted Photodynamic therapy), a targeted oncology platform for the treatment of solid tumors. The platform uses the drug Padeliporfin activated by targeted laser light to selectively destroy tumor vasculature, with a development pipeline targeting UTUC, lung, esophageal, and pancreatic cancers.

Product overview

ImPact Biotech (Steba Biotech) operates a single-platform approach built around its core Padeliporfin VTP (Vascular Targeted Photodynamic) technology. This novel oncology platform is designed to treat solid tumors by using light-activated therapy that targets tumor vasculature. The platform is being applied across multiple cancer indications in the development pipeline, including Upper Tract Urothelial Carcinoma (UTUC), Lung Cancer, Esophageal Cancer, and Pancreatic Cancer. The VTP technology offers surgery-like efficacy as an alternative for patients who are ineligible for surgery or for whom surgery would be debilitating.

Differentiator

Problem solved

Functional benefit

Products and services

  • Padeliporfin VTP (Vascular Targeted Photodynamic Therapy) Padeliporfin VTP is a proprietary photo-activated oncology platform that uses the drug Padeliporfin combined with targeted laser light to selectively destroy tumor vasculature. It is being developed as a treatment for solid tumors and is intended for oncology specialists and hospital oncology/urology departments.
  • Padeliporfin VTP for Upper Tract Urothelial Carcinoma (UTUC) An application of Steba Biotech's Padeliporfin VTP platform targeting Upper Tract Urothelial Carcinoma (UTUC), a rare urological cancer of the upper urinary tract. In development stage, intended for urology and oncology specialists treating UTUC patients.
  • Padeliporfin VTP for Lung Cancer An application of Steba Biotech's Padeliporfin VTP platform targeting lung cancer. In development stage, intended for thoracic oncologists and pulmonology/oncology departments.
  • Padeliporfin VTP for Esophageal Cancer An application of Steba Biotech's Padeliporfin VTP platform targeting esophageal cancer. In development stage, intended for gastroenterology oncologists and oncology departments.
  • Padeliporfin VTP for Pancreatic Cancer An application of Steba Biotech's Padeliporfin VTP platform targeting pancreatic cancer. In development stage, intended for gastrointestinal oncologists and oncology surgical departments.

Companies that use Steba Biotech

Customer profile

Segments1 record

Ideal customer profiles1 record

Steba Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Steba Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Open to PartneringcoreStrategic or Co-development PartnerImPact Biotech is actively seeking partnerships with organizations that share their vision for transforming the treatment paradigm in oncology. The company emphasizes that transforming treatment paradigms requires both innovation and strong collaborations. They welcome inquiries from organizations interested in working with ImPact Biotech to advance their VTP technology platform.

Recent moves3 records

Expansion highlights4 records

Steba Biotech competitors and assessment

Company assessment

Direct peers

  • Rakuten Medical: Rakuten Medical develops photoimmunotherapy (Alluminox platform), a light-activated oncology therapy that selectively targets tumor cells. It is the most directly comparable peer to ImPact Biotech, as both pursue light-activated, vascular- or cell-targeted oncology platforms in solid tumors.
  • Theralase Technologies: Theralase is a clinical-stage photodynamic therapy company developing light-activated drug conjugates for non-muscle invasive bladder cancer and other solid tumors. It competes with ImPact Biotech in the PDT-oncology space, particularly for urological indications like UTUC.
  • PhotoCure: PhotoCure commercializes Hexvix/Cysview, a photodynamic diagnostic and therapy platform used in bladder cancer management. It is a directly relevant peer in the PDT space and shares the urology-oncology overlap relevant to ImPact Biotech's UTUC program.
  • Biolitec Pharma: Biolitec develops and commercializes laser-based photodynamic therapy systems and photosensitizing drugs for multiple solid tumor and benign indications. It is a direct commercial peer in the broader oncology PDT market.
  • UroGen Pharma: UroGen Pharma develops specialty therapeutics for urothelial cancers, including Jelmyto for upper tract urothelial carcinoma (UTUC) — the same lead indication targeted by ImPact Biotech. It is a directly relevant peer for the UTUC opportunity.

Emerging players

  • Soligenix: Soligenix is developing SGX301 (synthetic hypericin) photodynamic therapy for cutaneous T-cell lymphoma and has oncology and PDT expertise. It is an emerging peer with narrower indications but a directly comparable light-activated oncology mechanism.

Others

  • Modulight: Modulight manufactures medical laser systems used as the light-delivery component in photodynamic therapy, including oncology applications. It is a key enabling technology supplier to PDT developers like ImPact Biotech rather than a direct competitor.

Broad incumbents

  • AstraZeneca: AstraZeneca is a broad incumbent in oncology with approved therapies across lung, esophageal, and other solid tumors that overlap with ImPact Biotech's pipeline indications. It is relevant as a competitive force and a potential strategic acquirer or partner.
  • Bristol-Myers Squibb: Bristol-Myers Squibb is a major oncology incumbent with leading immunotherapy franchises (Opdivo, Yervoy) targeting lung and other solid tumors overlapping with ImPact Biotech's pipeline. It represents the competitive standard of care in multiple ImPact indications.
  • Jazz Pharmaceuticals: Jazz Pharmaceuticals markets Zepzelca (lurbinectedin) for small cell lung cancer and has a broader oncology specialty franchise, including in urological cancers. It is a relevant commercial peer in ImPact Biotech's lung and UTUC indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Steba Biotech social profiles

Digital presence

Steba Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Steba Biotech leadership team

Management profile

Number of profiles

Profiles2 records

Steba Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Steba Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Steba Biotech

What does Steba Biotech do?

Steba Biotech (operating as ImPact Biotech) is a private biopharmaceutical company developing Padeliporfin VTP (Vascular Targeted Photodynamic therapy), a targeted oncology platform for the treatment of solid tumors. The platform uses the drug Padeliporfin activated by targeted laser light to selectively destroy tumor vasculature, with a development pipeline targeting UTUC, lung, esophageal, and pancreatic cancers.

Is Steba Biotech a public or private company?

Steba Biotech is a private company. It is classified as unknown and is currently operating.

When was Steba Biotech founded?

Steba Biotech was founded in 1996. It employs 11 to 50 people.

Where is Steba Biotech based?

Steba Biotech is headquartered in New York, United States, in the North America region.

Who are Steba Biotech's main competitors?

Direct peers on record are Rakuten Medical, Theralase Technologies, PhotoCure, Biolitec Pharma and UroGen Pharma. Soligenix is listed as an emerging player. Modulight is listed as an others. Broad incumbents are AstraZeneca, Bristol-Myers Squibb and Jazz Pharmaceuticals.

Does Steba Biotech have an API?

No public API is recorded for Steba Biotech.

What industry is Steba Biotech in?

Steba Biotech's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSteba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial CancerSteba Biotech treated the first patient in its Phase 3 ENLIGHTED trial of Padeliporfin ImPACT for low-grade upper tract urothelial cancer. The multi-center study will recruit 100 patients with induction and maintenance phases, with primary endpoint data expected in 2022 and submission in 2023.GlobeNewswireSteba Biotech receives FDA Orphan Drug Designation for Padeliporfin ImPACT in Upper Tract Urothelial CancerSteba Biotech announced the FDA granted Orphan Drug Designation to Padeliporfin ImPACT for upper tract urothelial cancer. The pivotal Phase 3 trial is expected to begin enrollment later this month, with the company aiming to offer organ preservation. The designation also includes Fast Track status and seven-year marketing exclusivity.PR NewswireFDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba biotechSteba biotech announced that the U.S. Food and Drug Administration granted Fast Track designation for padeliporfin ImPACT to treat adult patients with low-grade and unifocal high-grade Upper Tract Urothelial Cancer (UTUC). The designation follows IND clearance in December 2020 and enables the pivotal Phase 3 clinical trial to begin enrollment in Q1 2021, accelerating the drug's regulatory review timeline. The company is developing ImPACT as an oncology platform offering surgery-like efficacy combined with organ preservation for solid tumors where surgical risks are high.PR NewswireSteba Biotech's TOOKAD® Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 YearsSteba Biotech announced 4-year follow-up data from the PCM301 trial of TOOKAD vascular photodynamic therapy for low-risk prostate cancer. Conversion to radical therapy was 24% vs 53% at 4 years (HR=0.31, p<0.001). The company expects European availability soon.